News & Media

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces a good market uptake and strong sales development for simeprevir during the first...

Press release 2014/04/12 Regulatory

Final data from the phase II COSMOS study with Simeprevir in combination with Sofosbuvir presented at EASL

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that positive new simeprevir data were presented at The International Liver Congress™...

Press release 2014/04/07 Regulatory

Annual Report 2013

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the Annual Report for 2013 now is available at the company’s...

Press release 2014/04/07 Regulatory

Notice of Annual General Meeting of Medivir AB (publ)

The shareholders in Medivir AB are hereby summoned to the annual general meeting on Thursday 8 May 2014 at 2 p.m....

Press release 2014/04/02 Regulatory

Two phase III trials evaluating once-daily Simeprevir and Sofosbuvir in hepatitis C infected patients have been initiated

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that two phase III trials are recruiting patients to examine the efficacy...

Press release 2014/03/24 Regulatory

New Simeprevir data will be presented at The International Liver Congress 2014 of the European Association for the Study of the Liver, (EASL)

Presentations Include late-breaking final results from the phase II COSMOS study Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that...

Press release 2014/03/24 Regulatory

Simeprevir has now been approved in Russia

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced today that that the Russian Ministry of Health has approved Sovriad® (simeprevir) for...

Press release 2014/03/21 Regulatory

Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union

Positive opinion for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC)...

Press release 2014/03/17 Regulatory

New Phase III Data from Once-Daily Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL)

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that new phase III data for the once-daily protease inhibitor simeprevir have...

Press release 2014/03/14 Regulatory

The Nomination Committee’s proposal, with reference to the upcoming 2014 Annual General Meeting, for a new Board of Directors

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced today the Nomination Committee’s proposal, with reference to the upcoming 2014 Annual General...

Press release 2014/03/04 Regulatory

SVR12 results from a phase IIa study evaluating Simeprevir and Daclatasvir in Hepatitis C patients of genotype 1 have been presented

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that study results from a phase IIa trial evaluating simeprevir, a once-daily...

Press release 2014/02/24 Regulatory

Financial Statement, 1 January – 31 December 2013*

Financial summary for the year as a whole. Continuing Group operations, excluding Cross Pharma. Net turnover totalled SEK 446.1 million (SEK...